20895-62-9Relevant articles and documents
Analogues of Acifran: Agonists of the high and low affinity niacin receptors, GPR109a and GPR109b
Jung, Jae-Kyu,Johnson, Benjamin R.,Duong, Tracy,Decaire, Marc,Uy, Jane,Gharbaoui, Tawfik,Boatman, P. Douglas,Sage, Carleton R.,Chen, Ruoping,Richman, Jeremy G.,Connolly, Daniel T.,Semple, Graeme
, p. 1445 - 1448 (2007/10/03)
Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.
Rhodium-catalyzed addition of arylstannanes to carbon-heteroatom double bond
Oi, Shuichi,Moro, Mitsutoshi,Fukuhara, Hiroe,Kawanishi, Takanori,Inoue, Yoshio
, p. 4351 - 4361 (2007/10/03)
The addition of arylstannanes to the carbon-heteroatom double bond in the presence of a catalytic amount of a cationic rhodium complex ([Rh(cod)(MeCN)2]BF4) was examined. The reactions of aldehydes, α-dicarbonyl compounds, and N-substituted aldimines with the arylstannanes gave corresponding alcohols, α-hydroxy carbonyl compounds, and amines, respectively. An arylrhodium complex generated by the transmetalation with the arylstannane was probably the active catalytic species.
